2020 2019 2018 2017 2016

Shore, ND, Crawford, ED, Szmulewitz, RZ, Holzbeierlein, DPJ, Holzbeierlein, J, Villers, A, Azad, A, Alcaraz, A, Alekseev, B, Iguchi, T, Gomez-Veiga, F, Rosbrook, B, Baron, B, Haas, GP, Stenzl, A, Armstrong, AJ. Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT. SWISS MED WKLY 25-26. 18 nov 2020. . . F.I.:2,193 

Gomez-Veiga, F, Asensio, AA, Revilla, JB, Olmo, JC. Advances in urologic oncology "OncoForum": The best of 2019. ACTAS UROL ESP 44 586-596. 1 nov 2020. . . F.I.:0,994 [doi:10.1016/j.acuro.2020.06.007]
Alcaraz, A, Szmulewitz, RZ, Shore, N, Crawford, ED, Petrylak, DP, Holzbeierlein, J, Villers, A, Azad, AA, Alekseev, B, Iguchi, T, Gomez-Veiga, F, Rosbrook, B, Sugg, J, Haas, GP, Stenzl, A, Armstrong, AJ. ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels. ANN ONCOL 31 523-524. 1 sep 2020. . . F.I.:32,976 [doi:10.1016/j.annonc.2020.08.894]

Chowdhury, S, Bjartell, A, Lumen, N, Maroto, P, Paiss, T, Gomez-Veiga, F, Birtle, A, Kramer, G, Kalinka, E, Spaeth, D, Feyerabend, S, Matveev, V, Lefresne, F, Lukac, M, Wapenaarls, R, Costa, L. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. TARGET ONCOL 15 301-315. 1 jun 2020. 1 jun 2020. . F.I.:4,493 [doi:10.1007/s11523-020-00720-2]

Shore, ND, Armstrong, AJ, Szmulewitz, RZ, Petrylak, DP, Holzbeierlein, J, Villers, A, Azad, A, Alcaraz, A, Alekseev, B, Iguchi, T, Gomez-Veiga, F, Rosbrook, B, Lee, HJ, Haas, GP, Stenzl, A. Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.. J CLIN ONCOL 38 -. 20 may 2020. . . F.I.:44,544 
Rodriguez, AJV, Asensio, SM, Polo, MH, Sanchez, TH, Ruiz, AS, Garcia, F, Vesga, F, Gutierrez, E, Serrano, JM, Calleja, J, Cortinas, JR, Zamora, A, Rodriguez, V, Sesmero, JHA, Szczesniewski, RJ, Martinez, SV, Lopez, CP, Gala, L, Campanario, F, Barcina, A, Aramburu, MAL, Moya, I, Bermudez, R, Veiga, FG. The impact of time from biopsy to radical prostatectomy on Gleason score undergrading and other related factors. ACTAS UROL ESP 44 187-195. 1 abr 2020. . . F.I.:0,994 [doi:10.1016/j.acuro.2019.08.004]
Garcia-Rodriguez, J, Fernandez-Gomez, JM, Cozar, JM, Minana, B, Gomez-Veiga, F, Rodriguez-Antolin, A, Grp Espanol Canc Prostata GESCAP. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. ACTAS UROL ESP 44 156-163. 1 abr 2020. . . F.I.:0,994 [doi:10.1016/j.acuro.2019.06.006]
Shore, ND, Crawford, ED, Szmulewitz, RZ, Petrylak, D, Holzbeierlein, J, Villers, A, Azad, A, Alcaraz, A, Alekseev, B, Iguchi, T, Gomez-Veiga, F, Rosbrook, B, Baron, B, Haas, GP, Stenzl, A, Armstrong, AJ. IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY. J UROLOGY 203 249-250. 1 abr 2020. . . F.I.:7,450 
Armstrong, Andrew J, Shore, Neal D, Szmulewitz, Russell Z, Petrylak, Daniel P, Holzbeierlein, Jeffrey, Villers, Arnauld, Azad, Arun, Alcaraz, Antonio, Alekseev, Boris, Iguchi, Taro, Gomez-Veiga, Francisco, Rosbrook, Brad, Lee, Ho-Jin, Haas, Gabriel P, Stenzl, Arnulf. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.. J UROLOGY 205 1361-1370. 1 ene 2020. . . F.I.:7,450 [doi:10.1097/JU.0000000000001568]